안허혈증후군 환자에게 유리체강내 베바시주맙 주입 후 발생한 급격한 시력저하 = Acute Visual Loss after Intravitreal Bevacizumab Injection in a Patient with Ocular Ischemic Syndrome

다국어 초록 (Multilingual Abstract)

Purpose: To report a patient with ocular ischemic syndrome who suffered from sudden decrease in visual acuity after bevacizumab injection. Case summary: A 70-year-old patient visited the Department of Ophthalmology due to progressively decreasing visual acuity in the right eye. Corrected visual acuity in his right eye was 0.1 on the first visit; ocular ischemic syndrome was suspected. Despite panretinal photocoagulation, severe iris neovascularization was still present in the right eye. Intravitreal bevacizumab injection was performed to regress the iris neovascularization. One day after injection, iris neovascularization regressed significantly, however, visual acuity was decreased to finger counting. Conclusions: In ocular ischemic syndrome, bevacizumab injection for reduction of iris neovascularization should be carefully considered due to possibility of acute visual loss.

참고문헌 (Reference)

1 Peters S, "Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab" 143 : 995-1002, 2007

2 Brown GC, "The ocular ischemic syndrome. Clinical, fluorescein angiographic and carotid angiographic features" 11 : 239-251, 1988

3 Gheith ME, "Role of intravitreal bevacizumab in neovascular glaucoma" 23 : 487-491, 2007

4 Avery RL, "Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment" 26 : 352-354, 2006

5 Na Rae Kim, "Progression of Impending Central Retinal Vein Occlusion to the Ischemic Variant Following Intravitreal Bevacizumab" 대한안과학회 24 (24): 179-181, 2010

6 Kofoed PK, "Profound retinal ischaemia after ranibizumab administration in an eye with ocular ischaemic syndrome" 88 : 808-810, 2010

7 Sharma S, "Ocular ischemic syndrome, In Retina, 4th ed" Mosby 2006

8 Kim KS, "Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion" 86 : 925-927, 2008

9 Amselem L, "Intravitreal bevacizumab(Avastin) injection in ocular ischemic syndrome" 144 : 122-124, 2007

10 Avery RL, "Intravitreal bevacizumab(Avastin) in the treatment of proliferative diabeticretinopathy" 113 : 1695-, 2006

11 Wakabayashi T, "Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases" 115 : 1571-1580, 2008

12 이상준, "Intravitreal Bevacizumab (Avastin) Treatment of Neovascular Glaucoma in Ocular Ischemic Syndrome" 대한안과학회 23 (23): 132-134, 2009

13 Chalam KV, "Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma" 18 : 255-262, 2008

14 Ferrara N, "Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer" 3 : 391-400, 2004

15 Shima C, "Complications in patients after intravitreal injection of bevacizumab" 86 : 372-376, 2008

16 제유진, "Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes" OXFORD UNIV PRESS 22 (22): 1404-1412, 201106

17 Huang ZL, "Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome" 224 : 86-89, 2010